Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Strong Support for Treat-to-Target Strategy in RA Patients

Megan Brooks  |  

RA BIODAM is supported by an unrestricted grant from AbbVie, which sells anti-rheumatic drugs. Several authors, including Dr. Ramiro, disclosed relationships with the company.

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Ramiro S, Landewé RB, van der Heijde D, et al. Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann Rheum Dis. 2020 Feb 24. pii: annrheumdis-2019-216819. [Epub ahead of print]

Related Articles

    Treat to Target in axSpA

    PHILADELPHIA—Treat to target (T2T) is a common phrase in rheumatology these days—and a welcome one.1 Many of us are familiar with what T2T means in rheumatoid arthritis (RA), but we may be less sure of its meaning in axial spondyloarthritis (axSpA). At ACR Convergence 2022, Alexis Ogdie, MD, associate professor of medicine and epidemiology, University of…

    Target Remission

    Strategies to identify and track remission in your RA patients

    Study Finds Health & Financial Benefits in AxSpA Treat-To-Target Strategy

    EULAR 2020 e-CONGRESS—In what speakers at the European e-Congress of Rheumatology described as the first treat-to-target and tight control (T2T/TC) strategy trial in axial spondyloarthritis (AxSpA), researchers found such a strategy has both health and financial benefits. In the year-long study—called TICOSPA—centers were randomized to apply either a T2T/TC strategy or care left to the…